Dracen Announces DRP-104 (sirpiglenastat) Presentation at ASCO 2021 Virtual Annual Meeting
Share Article
Trial in progress poster: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors NEW YORK (PRWEB) June 03, 2021 Dracen Pharmaceuticals Inc., announced today that a poster presentation updating the ongoing Phase 1/2a, FIH study of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors will be presented during the trial in progress session at the ASCO virtual meeting June 4th- 8th, 2021.
The presentation details are as follows: Title: Phase 1 & Phase 2a, first-in-human study (FIH) of DRP-104, a broad glutamine antagonist, in adult patients with
Dracen Announces DRP-104 (sirpiglenastat) Presentations at AACR Virtual Annual Meeting
Share Article
Posters further expand on preclinical immuno-oncology mechanism of action and combination therapy with various checkpoint inhibitors and confirm DRP-104 single agent activity in KEAP1 and STK11 mutant lung tumors and head and neck squamous cell carcinoma New York, NY (PRWEB) April 05, 2021 Dracen Pharmaceuticals, Inc., announced today that three posters profiling its clinical stage glutamine antagonist, DRP-104 (sirpiglenastat), will be presented Saturday, April 10 - Monday, June 21 during the American Association for Cancer Research (AACR) Virtual Annual Meeting.
“As our lead asset DRP-104 (sirpiglenastat) advances in phase I clinical development, our preclinical data continues to confirm its promising profile both as a single agent and in combination therapy,” said Robert Wild, Ph.D., chief scientific off